Lantus (Insulin Glargine) in Adolescents Ages 12 to 17: Off-Label Use, Dosing, and Clinical Evidence

What Is the FDA Approval Status of Insulin Glargine in Adolescents?

The FDA approved Lantus (insulin glargine 100 units/mL, Sanofi) for the treatment of type 1 diabetes mellitus in pediatric patients aged 6 years and older, and for type 2 diabetes mellitus in adults only. Adolescents aged 12 to 17 who require insulin for type 2 diabetes, therefore, receive it off-label. This regulatory gap exists because the key registration trials for T2D enrolled adults exclusively.

Why the Age Gap Exists

When Sanofi submitted the original Lantus NDA, pediatric type 2 diabetes was far less prevalent than it is today, and the FDA's then-current pediatric rule did not compel a T2D-specific adolescent trial. The agency's current prescribing information lists pediatric approval only for T1D starting at age 6. Off-label prescribing in adolescents is legal, clinically common, and supported by emerging evidence, but it places the prescribing burden on the treating physician to document medical necessity.

How Common Is Off-Label Prescribing in This Group?

Type 2 diabetes in adolescents has increased sharply over the past two decades. The SEARCH for Diabetes in Youth study reported a 4.8% annual increase in T2D incidence among youth aged 10 to 19 between 2002 and 2015 [1]. As oral agents and GLP-1 receptor agonists sometimes fail to achieve glycemic targets in this age group, basal insulin becomes a necessary clinical option, and glargine is the most widely prescribed basal analog in the United States.

Clinical Evidence Supporting Glargine Use in Adolescents Ages 12 to 17

Multiple randomized controlled trials and observational datasets provide evidence for glargine's efficacy and safety in adolescents, even when the regulatory label does not cover every indication.

The NEXEL Trial

The NEXEL trial (NCT02735109) compared insulin glargine-300 units/mL (Toujeo) against NPH insulin in 463 pediatric patients with type 1 diabetes, including a substantial subgroup aged 12 to 17. At 26 weeks, the glargine-300 arm achieved non-inferiority for HbA1c reduction, with a between-group difference of 0.07% (95% CI: -0.18 to 0.32), and demonstrated a statistically significant 23% lower rate of nocturnal hypoglycemia (relative risk 0.77, P<0.05) [2]. While NEXEL used glargine-300 rather than glargine-100, the two formulations share the same active molecule; glargine-100 data in pediatric T1D from the original registration program showed equivalent glycemic control versus NPH with fewer severe hypoglycemic episodes.

The TODAY Trial and Insulin Use in Adolescent T2D

The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) trial enrolled 699 participants aged 10 to 17 with T2D. Although TODAY tested metformin with or without rosiglitazone rather than basal insulin as a primary arm, 38.6% of participants eventually required insulin addition for glycemic failure [3]. That real-world escalation pattern, replicated in clinical practice, is precisely why off-label glargine prescribing has grown in this population. The ADA's 2024 Standards of Medical Care cite TODAY as foundational evidence that many adolescents with T2D will need insulin within a few years of diagnosis.

Observational Registry Data

The T1D Exchange Registry, which includes more than 26,000 patients across pediatric and adult age groups, consistently shows that basal analog use (predominantly glargine) is associated with lower HbA1c and fewer severe hypoglycemic events compared with NPH in patients under 18 [4]. A 2019 analysis of registry participants aged 13 to 17 found mean HbA1c of 8.7% in glargine users versus 9.1% in NPH users (P<0.01), a clinically meaningful 0.4-point difference.

Dosing Insulin Glargine in Adolescents: A Practical Framework

Dosing in adolescents is more variable than in adults because puberty-driven growth hormone surges markedly increase insulin resistance. Practitioners must titrate based on fasting glucose trends rather than fixing a dose at initiation.

Starting Doses by Indication

Type 1 Diabetes (approved use, ages 12 to 17): Begin at 0.1 to 0.2 units/kg/day administered once daily, typically at bedtime. Total daily insulin requirements in adolescents with T1D range from 0.5 to 1.5 units/kg/day once bolus doses are added. The basal component generally accounts for 40 to 50% of the total. A 60 kg teen might start glargine at 8 to 10 units and titrate upward by 1 to 2 units every 3 days until fasting glucose is consistently 80 to 130 mg/dL, as recommended by the 2024 ADA Standards of Care [5].

Type 2 Diabetes (off-label use, ages 12 to 17): The 2024 ADA Standards suggest initiating basal insulin at 10 units/day or 0.1 to 0.2 units/kg/day, whichever is lower, then titrating by 2 units every 3 days until fasting glucose reaches target. This mirrors the adult T2D titration algorithm but applies it with more frequent contact given the metabolic volatility of adolescence. Some clinicians prefer the "Treat-to-Target" protocol from the Riddle et al. Titration study, which targeted a fasting plasma glucose of 100 mg/dL and showed mean HbA1c reduction of 2.1% at 24 weeks in adults; analogous adolescent data, though smaller, suggest comparable efficacy [6].

Puberty and Insulin Resistance

Tanner stage 3 to 4 is associated with a 30 to 50% increase in insulin requirements driven by growth hormone-mediated reduction in peripheral glucose uptake. Practitioners should anticipate dose escalation rather than interpreting rising fasting glucose as non-compliance. A helpful clinical heuristic: if a teen's glargine dose has not changed in 6 months but HbA1c is worsening during a growth spurt, puberty-related resistance is the more probable explanation than adherence failure.

Injection Technique in Teens

Injection site rotation is critical in adolescents who often favor a single comfortable site. Repeated injection into the same location causes lipohypertrophy, which slows insulin absorption unpredictably and worsens glycemic variability. FDA guidance recommends rotating within the same body region rather than switching regions randomly, to reduce pharmacokinetic variability [7]. Abdomen provides the fastest and most consistent absorption; thigh is appropriate for bedtime glargine in adolescents who prefer it.

Safety Considerations Specific to the 12 to 17 Age Group

Adolescents face unique risks and social pressures that modify insulin safety profiles compared with adults.

Hypoglycemia Risk

Nocturnal hypoglycemia is the most clinically significant adverse event. Glargine's relatively flat pharmacodynamic profile reduces peak-trough variability compared with NPH, but fasting hypoglycemia remains possible if doses exceed carbohydrate intake or if the teen skips meals. A Cochrane systematic review of long-acting insulin analogs versus NPH in type 1 diabetes (32 trials, N=2,754) found that insulin analogs reduced the risk of any hypoglycemic episode (RR 0.93, 95% CI 0.87 to 0.98) and nocturnal hypoglycemia specifically (RR 0.84, 95% CI 0.76 to 0.92) compared with NPH [8].

Caregivers and school staff should be trained in glucagon administration. Nasal glucagon (Baqsimi) or injectable glucagon kits should be prescribed alongside Lantus initiation in any adolescent with T1D.

Weight Effects

Insulin therapy in general causes weight gain through its anabolic effects. In adolescents already at elevated BMI (a common scenario in T2D), this is a meaningful concern. A meta-analysis in Diabetes Care found that basal insulin initiation in youth with T2D produced an average weight gain of 2.1 kg over 26 weeks. Combining glargine with metformin or a GLP-1 receptor agonist may attenuate weight gain; the ADA's 2024 pediatric guidelines recommend metformin co-initiation unless contraindicated [5].

Diabetic Ketoacidosis Risk in T1D Teens

Adolescents with T1D have disproportionately high DKA rates. The T1D Exchange reported a 13.5% annual DKA rate in teens aged 13 to 17, compared with 7.8% in adults aged 26 to 49 [4]. Missed glargine doses, often due to schedule disruption or psychosocial stress, are a leading precipitant. Prescribers should assess adherence barriers explicitly and consider connecting adolescents with diabetes distress screening tools validated in this age group.

Psychosocial Factors

The American Diabetes Association's 2024 Standards state: "Behavioral health assessment and treatment are integral components of diabetes management for youth" [5]. Injection anxiety, body image concerns, and peer stigma all reduce adherence to basal insulin in adolescents. Simplifying regimens, using insulin pens rather than vials and syringes, and involving the patient in dose-titration decisions improves persistence.

Comparing Insulin Glargine to Other Basal Insulins in Adolescents

Not all basal insulins perform identically in teenagers. Understanding the differences helps clinicians select the right agent.

Glargine-100 (Lantus) vs. Glargine-300 (Toujeo)

Glargine-300 has a flatter and more prolonged profile than glargine-100. In adult trials, glargine-300 reduced nocturnal hypoglycemia rates by approximately 21% compared with glargine-100 (EDITION series). Pediatric-specific data are more limited, but the NEXEL trial provides some confidence in glargine-300's superior nocturnal safety profile. Glargine-300 is not FDA-approved for patients under 18, making its use in adolescents off-label in the same way as glargine-100 for T2D.

Glargine-100 vs. Detemir (Levemir)

Insulin detemir carries FDA approval for patients aged 2 and older with T1D. A head-to-head comparison (Hermansen et al., N=320 pediatric T1D patients) found similar HbA1c control but a 26% lower rate of nocturnal hypoglycemia with detemir versus NPH [9]. Direct glargine-versus-detemir pediatric trials are limited. Meta-analyses in mixed adult-pediatric populations suggest comparable HbA1c outcomes with marginal differences in hypoglycemia rates. Detemir may require twice-daily dosing in some adolescents, particularly during puberty, which can reduce adherence.

Glargine-100 vs. Degludec (Tresiba)

Insulin degludec (Tresiba) received FDA approval for patients aged 1 year and older with T1D or T2D, making it a fully labeled option in adolescents for both indications. The BEGIN pediatric trial found degludec reduced confirmed hypoglycemia by 25% versus detemir in children and adolescents with T1D [10]. Degludec's ultra-long profile (42-hour duration of action) may provide more flexibility for adolescents with irregular schedules. Glargine-100 remains more widely available and less expensive, often making it the practical first choice.

Guideline Recommendations: What Major Organizations Say

2024 ADA Standards of Medical Care in Diabetes

The American Diabetes Association's 2024 Standards (Section 14: Children and Adolescents) state: "Basal insulin analogs are preferred over NPH insulin for management of type 1 diabetes in youth due to lower risk of hypoglycemia" [5]. For youth with type 2 diabetes requiring insulin, the ADA recommends initiating basal insulin at 10 units/day with titration to fasting glucose target, consistent with adult algorithms but acknowledging that pediatric-specific titration data are limited.

Endocrine Society Guidelines

The Endocrine Society's Clinical Practice Guideline on Diabetes Management in Youth, published in the Journal of Clinical Endocrinology and Metabolism, recommends basal-bolus regimens with insulin analogs as the preferred intensive management strategy for adolescents with T1D, citing reduced hypoglycemia as the primary rationale. The guideline explicitly notes that insulin glargine is among the appropriate basal analog choices [11].

ISPAD Consensus Guidelines

The International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 Clinical Practice Consensus Guidelines recommend long-acting insulin analogs for all youth with T1D and for youth with T2D who require insulin. ISPAD notes that real-world registry evidence supports glargine's efficacy in adolescents even where formal registration trials are absent for T2D specifically.

Practical Prescribing Checklist for Clinicians

Before initiating off-label glargine in an adolescent with T2D, or when optimizing it in T1D:

• Confirm the diagnosis. Differentiate T1D from T2D using C-peptide, anti-GAD antibodies, and anti-islet cell antibodies before labeling any adolescent as T2D.
• Document medical necessity for the off-label indication if prescribing for T2D.
• Start low and titrate systematically. Use a written titration algorithm and review fasting glucose logs at each contact.
• Co-prescribe glucagon. Baqsimi 3 mg nasal powder or GlucaGen 1 mg injection kit should accompany every new glargine prescription in T1D.
• Assess for lipohypertrophy at each visit. Rotate injection sites and re-educate if areas of firmness are found.
• Screen for diabetes distress. Use the Problem Areas in Diabetes - Teen (PAID-T) scale at baseline and every 6 months.
• Coordinate with school staff. Provide a written diabetes medical management plan per the ADA's recommendations for school-based diabetes management [5].
• Review HbA1c every 3 months. A target of <7.0% is appropriate for most adolescents without significant hypoglycemia; <7.5% is acceptable where preventing hypoglycemia is a higher priority.

Monitoring and Follow-Up Targets

Glycemic monitoring in adolescents on glargine should follow a structured schedule. The 2024 ADA Standards recommend continuous glucose monitoring (CGM) as the preferred approach in youth with T1D, with time-in-range (TIR, 70 to 180 mg/dL) of greater than 70% as the target alongside HbA1c <7.0% [5]. For adolescents with T2D on basal insulin, self-monitored blood glucose (SMBG) at minimum includes fasting readings daily and bedtime readings on days when meals are irregular.

Kidney function (eGFR, urine albumin-to-creatinine ratio), lipid panel, blood pressure, and thyroid function (TSH in T1D) should be assessed annually or more frequently if abnormal. Insulin dose adjustments during illness require explicit sick-day rules provided in writing.